| 000 | 01792 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516170111.0 | ||
| 264 | 0 | _c20140627 | |
| 008 | 201406s 0 0 eng d | ||
| 022 | _a2050-6511 | ||
| 024 | 7 |
_a10.1186/2050-6511-14-44 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYera-Alos, Isis B | |
| 245 | 0 | 0 |
_aActive post-marketing surveillance of the intralesional administration of human recombinant epidermal growth factor in diabetic foot ulcers. _h[electronic resource] |
| 260 |
_bBMC pharmacology & toxicology _cSep 2013 |
||
| 300 |
_a44 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAmputation, Surgical _xstatistics & numerical data |
| 650 | 0 | 4 |
_aDiabetic Foot _xdrug therapy |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEpidermal Growth Factor _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGranulation Tissue _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intralesional |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aProduct Surveillance, Postmarketing |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aWound Healing _xdrug effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aAlonso-Carbonell, Liuba | |
| 700 | 1 | _aValenzuela-Silva, Carmen M | |
| 700 | 1 | _aTuero-Iglesias, Angela D | |
| 700 | 1 | _aMoreira-Martínez, Martha | |
| 700 | 1 | _aMarrero-Rodríguez, Ivonne | |
| 700 | 1 | _aLópez-Mola, Ernesto | |
| 700 | 1 | _aLópez-Saura, Pedro A | |
| 773 | 0 |
_tBMC pharmacology & toxicology _gvol. 14 _gp. 44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/2050-6511-14-44 _zAvailable from publisher's website |
| 999 |
_c23059255 _d23059255 |
||